Zhang Jiandong, Belford Peter M, Stouffer George A
Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.
Division of Cardiology, Department of Medicine, University of North Carolina, Chapel Hill, NC 27514, USA.
J Clin Med. 2025 May 19;14(10):3554. doi: 10.3390/jcm14103554.
In late 2023, the U.S. Food and Drug Administration (FDA) approved two renal denervation (RDN) systems for the treatment of hypertension. Several professional societies, including the Society of Cardiovascular Angiography and Intervention (SCAI), the American Heart Association (AHA), and numerous European associations, have recognized the potential role of RDN in managing hypertension. Despite widespread enthusiasm from clinicians, patients, and the industry, the American Medical Association's Current Procedural Terminology (CPT) panel rejected the introduction of new codes for renal denervation at its September 2024 meeting. This article analyzes the latest evidence from clinical trials and registries, reviews current challenges in clinical practice, and explores the role of contemporary hypertension treatment from the perspective of interventional cardiologists.
2023年末，美国食品药品监督管理局（FDA）批准了两种用于治疗高血压的肾去神经支配（RDN）系统。包括心血管造影和介入学会（SCAI）、美国心脏协会（AHA）以及众多欧洲协会在内的多个专业学会，都认可了RDN在管理高血压方面的潜在作用。尽管临床医生、患者和行业对此普遍热情高涨，但美国医学协会现行程序术语（CPT）小组在其2024年9月的会议上拒绝引入肾去神经支配的新编码。本文分析了来自临床试验和注册研究的最新证据，回顾了临床实践中当前面临的挑战，并从介入心脏病学家的角度探讨了当代高血压治疗的作用。
